Overview

Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations

Status:
NOT_YET_RECRUITING
Trial end date:
2026-04-15
Target enrollment:
Participant gender:
Summary
Evaluating the efficacy of Neratinib tablets monotherapy in treating advanced solid tumors with HER2 mutations.
Phase:
PHASE2
Details
Lead Sponsor:
Convalife (Shanghai) Co., Ltd.
Treatments:
neratinib